Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
about
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.Impact of New Genomic Technologies on Understanding Adverse Drug ReactionsThe pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsPharmacogenomics of hypertension and heart diseasePharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Use of contemporary genetics in cardiovascular diagnosisGene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomesPharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next DecadeAnalysis of Genetic Variation in CYP450 Genes for Clinical ImplementationSurveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal GenomicsDetection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing DataGenetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomicsOpen access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicineA conceptual model for translating omic data into clinical actionMerging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data.The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.Towards a molecular systems model of coronary artery diseasePG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.Development of a multiplex and cost-effective genotype test toward more personalized medicine for the antiplatelet drug clopidogrel.Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.Clinical pharmacogenetics implementation: approaches, successes, and challengesCYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record.Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.Implementation and utilization of genetic testing in personalized medicine.Integration of genomics into the electronic health record: mapping terra incognita.Drug-gene interactions: inherent variability in drug maintenance dose requirementsCost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary interventionEmerging roles for pharmacists in clinical implementation of pharmacogenomicsPharmacogenetics in Jewish populations.Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysisGenetic factors affecting drug disposition in Asian cancer patients.Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia - a randomized, double-blind, double-dummy crossover study.Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCIPharmacogenomics in cardiology--genetics and drug response: 10 years of progress.
P2860
Q24567778-AF6F506D-D529-480A-A9CB-E17F3BBB24A0Q26787099-F419F73B-C8EC-4A61-BCFE-685E8C681831Q26801867-805BEBF2-21FC-4403-9AAA-5738A24A6131Q26822796-9D0BFED0-C41F-4508-A8C1-25A4F5760D02Q27015722-2E1141D9-E3BD-4600-A661-A21520D1624FQ27022443-467A3AA6-A1A1-49CC-B9C5-D7BAEF3D2D81Q27025306-5C07908E-A4B3-4853-ADC2-7C4CCA1D7EBBQ28247305-62D702F6-92C2-49CA-85F8-BA81CF0B38DAQ28392069-B22DE5F5-13A2-4CEF-8E3D-E5246B78C2F9Q28468449-33229A9A-27EB-475B-9745-B29317EFE237Q28542977-F48298F8-8B22-43A9-8337-DE829793BFF7Q28553076-3A05F5B5-6E2B-4AFF-A326-2888D401C0CBQ28601852-D7155A0B-B46B-49E8-B461-F65754B2D23BQ30487537-52D4C8F1-70EF-4F67-96E7-356789FA3C85Q31000681-40C553C4-FF3A-4484-9A92-FE1A6D7E5F60Q31058146-A392629D-E3C3-4A77-B6BB-8832F99BA682Q31157018-4FBDA667-CEBE-4F6F-8F78-5CD3D156E828Q33648022-0E0ECE23-35B2-4955-B267-C212E3CD5EBFQ33725390-FAC25DA8-0809-4ABF-B277-1F5EB42118A5Q33729494-B8C77FCC-D8AA-40B5-AC94-3683A1384760Q33751939-77BF32A9-EEC4-4E10-9C31-8CDB64F04309Q33755635-597D4B31-3C1E-45CD-998E-3873FE8858A7Q33792154-556A0402-0E6F-4014-86FE-B7E970154BDCQ33818356-8DD4B990-1418-46E5-B609-F8A743ED024DQ33825186-BC08E5B7-EB11-4303-A9F5-A3072FEEB765Q33849298-0D8B24F8-E63F-4E75-860B-877CD8073BEDQ33883530-ECCA49D1-C215-4F94-8FBD-DEF9A6D95360Q33963651-A5E35632-8292-4D29-BE83-64A9B4C6A30EQ34147916-FB364EAF-FC46-4E0E-85FB-6C2D9051B3C8Q34148149-D50E0F51-0496-4B10-AFAD-888BF281B998Q34154939-3877FEBE-7B0A-44B9-B981-4CFEA24D09ECQ34166239-2DCEC88A-7BBC-43B0-976B-79A270FFFBAFQ34302434-85FFB835-27B6-4979-825C-5EB8C7ED0FA4Q34458720-519A220F-0AEC-4837-979B-FA0CC32DDCAAQ34486149-C5392306-2E82-4ABF-84DF-1ABC82FF3E55Q34501025-49E6EF23-3906-4099-B265-47C2D41B709CQ34570910-14A981EC-C1B2-485E-BA58-92D2E149375DQ35719554-9255DF75-6698-4A6A-86C5-76B8533F5F01Q35764145-6DA5E917-0334-4947-9BA9-420F3803226BQ35769279-1466AC5A-5498-451D-93CB-AC3C5C6ACCF7
P2860
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical Pharmacogenetics Impl ...... pidogrel therapy: 2013 update.
@en
Clinical Pharmacogenetics Impl ...... pidogrel therapy: 2013 update.
@nl
type
label
Clinical Pharmacogenetics Impl ...... pidogrel therapy: 2013 update.
@en
Clinical Pharmacogenetics Impl ...... pidogrel therapy: 2013 update.
@nl
prefLabel
Clinical Pharmacogenetics Impl ...... pidogrel therapy: 2013 update.
@en
Clinical Pharmacogenetics Impl ...... pidogrel therapy: 2013 update.
@nl
P2093
P2860
P50
P356
P1476
Clinical Pharmacogenetics Impl ...... opidogrel therapy: 2013 update
@en
P2093
Clinical Pharmacogenetics Implementation Consortium
J A Johnson
K Sangkuhl
M S Sabatine
P2860
P304
P356
10.1038/CLPT.2013.105
P407
P577
2013-05-22T00:00:00Z